Clinical Trial Detail

NCT ID NCT03501368
Title Study of Ceritinib in Patients With Unresectable Melanoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Ceritinib

Age Groups: adult senior

No variant requirements are available.